BAY-2402234 Inhibitor

Name: BAY-2402234 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754581
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754581

BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment,of myeloid malignancies. BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

BAY-2402234, Inhibitor

Full Product Name

BAY-2402234

Product Gene Name

BAY-2402234, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

520.84

Solubility

DMSO: 124mg/mL (238.08mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C21H18ClF5N4O4

SMILES

CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O

CAS Number

2225819-06-5

Target & IC50

DHODH

In Vitro

BAY-2402234 exhibits strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models. BAY-2402234 induces AML differentiation in vivo as detected by upregulation of differentiation cell surface markers in xenograft and PDX models after treatment with the inhibitor. Target engagement of the novel DHODH inhibitor BAY-2402234 can be observed by increase of tumoral and plasma dihydroorotate levels after treatment with the inhibitor. Furthermore, differentiation-associated transcriptomic changes are evident following a single administration of BAY-2402234 in vivo[1].

Product Categories/Family for BAY-2402234, inhibitor

Metabolism; Dehydrogenase

Product References and Citations for BAY-2402234, inhibitor

Andreas Janzer, et al. Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment,of myeloid malignancies. AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL.
Andreas Janzer, et al. Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment,of myeloid malignancies. AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL.

Other Notes

Small volumes of BAY-2402234, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for BAY-2402234 purchase

MBS5754581 is an inhibitor targeting BAY-2402234.